Overview

Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma

Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
An International, Single-Arm, Multicenter Phase 2 Trial.
Phase:
Phase 2
Details
Lead Sponsor:
Y-mAbs Therapeutics
Treatments:
Irinotecan
Temozolomide